ライフサイエンスコーパス: relapse

1 terized by high rates of drug resistance and relapse.

2 ng the need of denser sampling of tumours at relapse.

3 s are associated with metastasis and disease relapse.

4 rence leading to drug resistance and disease relapse.

5 Methotrexate might be used in patients who relapse.

6 es, creating powerful, enduring triggers for relapse.

7 pen-treatment phase were not associated with relapse.

8 lly distinct interventions to prevent opioid relapse.

9 d and exhibited intrinsic drug resistance at relapse.

10 s, and for identifying those at high risk of relapse.

11 d initial ONI at diagnosis, and 5 had ONI at relapse.

12 PCa) recurrence in patients with biochemical relapse.

13 overall survival, relapse, and death without relapse.

14 to the treatment cohort, was used to predict relapse.

15 diated tumors can also develop, resulting in relapse.

16 addiction, causing cue-induced cravings and relapse.

17 disease progression, therapy resistance and relapse.

18 , which also show potential to predict early relapse.

19 of tumor initiation, disease progression and relapse.

20 cant treatment differences were observed for relapse.

21 efore treatment, potentially contributing to relapse.

22 d renal prognosis compared with patients who relapsed.

23 sequently developed clinical and virological relapses.

24 ous stem-cell transplantation, patients have relapses.

25 at persistence of MOG-IgG is associated with relapses.

26 w to accurately determine which patients are relapsing.

27 ts with a relapsing course (median number of relapses = 1, range: 1-6) appeared to have greater risk

28 atient, the CD19(-) clone appeared as a late relapse 19 months after completion of blinatumomab treat

29 Metaregression revealed higher rates of relapse (2.2; 95% CI, 1.2-4.0), failure (3.7; 95% CI, 1.

30 11p15 methylation status was associated relapse (20% relapse with loss of heterozygosity, 25% wi

31 The primary endpoint was ipsilateral local relapse (80% power to exclude a 2.5% increase [non-infer

32 neuromyelitis optica spectrum disorders and relapsing acute disseminated encephalomyelitis, and char

33 FU followed by GDC-0941 may suppress disease relapse after 5-FU-based gastric cancer chemotherapy.

34 idence of remission failure or hematological relapse after conventional chemotherapy.

35 We modeled the two phases of relapse after extinction from cocaine self-administratio

36 ction chemotherapy therapy or who experience relapse after initial response have dismal outcomes.

37 chronicity, are all risk factors for future relapse after interactions with CRTs.

38 t immunotherapies reduce the risk of disease relapse after resection of murine PDAC, suggesting this

39 y evaluated 50 PCa patients with biochemical relapse after surgery or external-beam radiation therapy

40 nts commonly exhibit poor prognosis and high relapse after treatment, but there remains a lack of bio

41 p to 50% of patients become refractory to or relapse after treatment.

42 ients and Methods Data from 185 patients who relapsed after adjuvant carboplatin between January 1987

43 eening who were either treatment naive to or relapsed after interferon-alpha based therapy.

44 cells expand in patients with MS and promote relapses after bystander recruitment to the CNS, whereas

45 nt of more severe forms of leishmaniasis and relapses after drug treatment in humans.

46 e sclerosis, where it reflects the remission/relapse alternation.

47 did not confer long-term protection against relapse, although it did delay relapse while patients we

48 nsplantation (autoSCT) to reduce the risk of relapse, although the benefit of this treatment strategy

49 Ls in vitro and prevented the development of relapsed AML in vivo.

50 iated with smoking sooner during the smoking relapse-analog task.

51 n conditioning regimen, in hopes of reducing relapse and decreasing graft rejection.

52 tence of alcohol addiction since it leads to relapse and for which there are few effective treatments

53 clinical scenarios that can be mistaken for relapse and how to accurately determine which patients a

54 biomarkers or therapeutic targets to prevent relapse and improve survival after allo-HCT.

55 throughout the study, those who had frequent relapse and remission, and those who had relentless seiz

56 .0%), out of which 29 (38.1%) had new vessel relapse and required additional laser treatment.

57 loid leukaemia and are associated with rapid relapse and short overall survival.

58 Primary outcomes were infection relapse and survival.

59 nd the genetic basis of clonal evolution and relapse and the role of inherited genetic variants in le

60 treatment, and incidence and localization of relapse and transformation.

61 Overall, 25 patients relapsed and 13 died.

62 Two cirrhotic patients relapsed and 2 discontinued treatment due to serious adv

63 can improve outcomes for some patients with relapsed and refractory disease, not all patients have a

64 tibody, at a dose of 200 mg every 3 weeks in relapsed and transformed CLL.

65 treatment options have become available for relapsed and/or refractory multiple myeloma (R/R MM) aft

66 actice, its ability to identify asymptomatic relapses and improve survival for patients is not well d

67 respond well to ADTs, the cancer inevitably relapses and progresses to lethal castration-resistant p

68 tation outcomes, including overall survival, relapse, and death without relapse.

69 in a mouse model of self-administration and relapse, and found that either increasing activity in D1

70 eneral agreement on definitions of response, relapse, and methods of determining minimal residual dis

71 stant metastasis-free survival, freedom from relapse, and safety.

72 improvement, long-term influence of alcohol relapse, and their interaction.

73 nce of other autoimmune diseases, to control relapses, and to evaluate psychophysical sequelae.

74 inued for 6-12 months to potentially prevent relapse; and (4) implementation of successful treatment

75 Central nervous system (CNS) relapses are an uncommon yet devastating complication of

76 Relapses are common (37.3%), especially in the first 72

77 patients remained abstinent and 53 patients relapsed as indicated by the Alcohol Timeline Followback

78 The TBI group had lower incidence of relapse at 1 year (15% vs 54%, P = 0.05).

79 vast majority of recovering alcoholics will relapse at least once and understanding how the brain re

80 ustained virological response, with one (1%) relapse at post-treatment week 8.

81 of 7.9 +/- 4.3 y (mean +/- SD), their total relapses averaged 4 +/- 2.4, and their Expanded Disabili

82 erapy is a novel treatment for refractory or relapsed B-cell malignancies.

83 reatment of an immunosuppressed patient with relapsing babesiosis.

84 he bladder, this treatment failed to prevent relapsing bacteriuria.

85 KRAS mutant and wild-type cells, and predict relapse based on increased cytarabine resistance of a KR

86 Shorter courses lead to high rates of relapse because subpopulations of bacilli can survive de

87 negative emotional state leading to chronic relapsing behavior.

88 ts (beta = 1.105, p < 0.001) and presence of relapses (beta = 1.430, p < 0.001).

89 ,637 patients, demonstrated similar risk for relapse between 8 weeks and 12 weeks of LDV/SOF (relativ

90 l alloreactivity in HCT can control leukemic relapse, but capturing alloreactivity in HLA-matched HCT

91 poside, and melphalan group had died without relapse by 5 years.

92 ergy intake from fat increased the hazard of relapse by 56% (adjusted HR 1.56, 95% CI 1.05 to 2.31, p

93 ogical deficits before they can respond, and relapses can occur unpredictably.

94 Distant and local relapses can occur, and in studies reporting only on MAL

95 Discounting relapses, children acquired equal numbers of new P. falc

96 in cerebrospinal fluid of MS patients during relapse compared with specimens acquired during remissio

97 ded periods of abstinence and longer time to relapse, compared with males.

98 olecular workup of 1 of the cases with early relapse confirmed this hypothesis by revealing a disrupt

99 Patients with a relapsing course (median number of relapses = 1, range:

100 ith an event defined as disease progression, relapse, death, allergy to rituximab, or severe infectio

101 However, after 6 weeks, risk of relapse did not significantly differ between the 2 group

102 STATEMENT Alcohol use disorder is a chronic relapsing disorder that is associated with compulsive al

103 Nine patients (56%) had a relapse during a mean follow-up of 36 (range, 24-47) mon

104 ntention-to-treat population, n=570) 24 week relapse events were greater for XR-NTX (185 [65%] of 283

105 ns that persisted from pain onset to 'out of relapse' follow-up (current MRI) had highly significant

106 ts who are at highest risk of experiencing a relapse following conventional therapy.

107 The early detection of relapse following primary surgery for non-small-cell lun

108 SC) and their progenitors in bone marrow and relapse following treatment cessation.

109 or drug taking, might be especially prone to relapse following treatment.

110 decades have revolutionized the treatment of relapsing forms of multiple sclerosis.

111 tandard regimen and reduce treatment time to relapse-free cure by 75%.

112 Results Relapse-free survival (RFS) and overall survival (OS) ra

113 Median relapse-free survival and overall survival were 6.7 and

114 ut not VGLL1-3, correlated with both shorter relapse-free survival and shorter disease-specific survi

115 e aimed to estimate the difference in opioid relapse-free survival between XR-NTX and BUP-NX.

116 The 5-year relapse-free survival is 82% (95% CI, 72 to 92).

117 9%; relapse, nonrelapse mortality, GVHD-free relapse-free survival, and overall survival at 1 year we

118 ssociated with a worse 5-year probability of relapse-free survival.

119 Alcohol relapse (>/=30 g/day) was not associated with mortality

120 Patients with frequent HSK relapses had lower QoL related to "ocular pain" and "ack

121 Relapse has emerged as the most important cause of treat

122 As outcomes after ibrutinib relapse have been reported to be poor, specific strategi

123 Models of relapse have demonstrated that neuroadaptations in rewar

124 TCL with primary refractory disease or early relapse have extremely poor survival.

125 limit of the two-sided 95% CI for the local relapse hazard ratio [HR] was less than 2.03), analysed

126 ion were associated with significantly lower relapse (hazard ratio [HR], 0.72; P = .004) and overall

127 Thirty-three patients with a unilateral and relapsing herpes simplex keratitis (HSK group) that was

128 all-comer patients with platinum-sensitive, relapsed high-grade serous ovarian cancer.

129 rtex circuit in a model highly predictive of relapse highlights the importance of social-emotional fu

130 iescent phase of the disease, unilateral and relapsing HSK significantly impairs the QoL of patients

131 xygenase (AGMO) gene were associated with KA relapse in 3 families.

132 -striatal projections control extinction and relapse in a rat model of alcohol seeking.

133 at reduce the impact that these cues have on relapse in alcoholics.

134 The risk of VL relapse in coinfected patients was high, particularly in

135 asculitis and the rate of neovascularization relapse in ischemic vasculitis.

136 survival and significantly reduced rates of relapse in lestaurtinib-treated patients who achieved su

137 strategy to prevent dissemination and overt relapse in multiple myeloma.

138 ll of this difference accounted for by early relapse in nearly all (70 [89%] of 79) XR-NTX induction

139 stic significance of CNA presence in disease relapse in patients with AML.

140 have not been shown to decrease the risk of relapse in patients with Crohn's disease.

141 h stressful life events increase the risk of relapse in recovering cocaine addicts are not well under

142 ents with the highest rates of prevention of relapse in schizophrenia.

143 in the Neuropsychiatric Inventory (NPI) and relapse in the first 16-week phase after randomization.

144 aquine is the only drug available to prevent relapse in vivax malaria.

145 ts with late recurrent viremia had virologic relapse in which the HCV present at baseline persisted i

146 ecursors should be targeted to avoid CD19(-) relapses in patients with BCR-ABL1-positive ALL.

147 were significantly associated with a higher relapse incidence and shorter OS.

148 ients; accrual ceased at 272 because of high relapse incidence with RIC versus MAC (48.3%; 95% CI, 39

149 isk, factors that increase the likelihood of relapse including histologic subtype, MYC rearrangement,

150 I < 15% (log-rank P = .002), and the rate of relapse increased by 24% with each 1-year increase in ag

151 80, respectively), whereas the occurrence of relapse increased this risk (HR, 95% CI = 5.08, 3.46-7.4

152 Tuberculosis relapse is a barrier to shorter treatment.

153 ABVD only could not be demonstrated: risk of relapse is increased when INRT is omitted, especially in

154 on of patients at high risk of secondary CNS relapse is therefore paramount.

155 Whole-genome comparison of pretreatment and relapse isolates of M. intracellulare uncovered mutation

156 uced cocaine reward-context associations and relapse-like behaviors in a cocaine self-administration

157 herapeutic approaches, and prognosis of late relapse (LR) in patients with classic Hodgkin lymphoma (

158 nge, 44-87 y) with prostate-specific antigen relapse (mean prostate-specific antigen level, 5 ng/mL;

159 tution study demonstrates that patients with relapsed metastatic GCT are curable by HDCT plus PBSCT e

160 of 1.23, 95% CI 1.13-1.34; p<0.0001) and non-relapse mortality (cause-specific HR for a two-fold chan

161 generation and more rapid remyelination make relapsing MS more resilient than the progressive subtype

162 s in approximately 30% of de novo and 70% of relapsed multiple myeloma (MM) and is correlated with di

163 randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous ocre

164 enrolled patients with primary refractory or relapsed myeloma who had received treatment with bortezo

165 imen for ASCT in patients with refractory or relapsed myeloma.

166 s (mean: 7.7 years) from the subconjunctival relapse, no further episodes of intraocular/extraocular

167 umulative incidence of chronic GVHD was 29%; relapse, nonrelapse mortality, GVHD-free relapse-free su

168 log-rank = .71), and cumulative incidence of relapse/nonresponse (CIR/NR; 6% +/- 3% vs 6% +/- 2%; PGr

169 ently suppressed the clonogenic potential of relapsed NRI AMLs in vitro and prevented the development

170 Relapse occurred in 812 (46%) of 1769 patients; 136 (9%)

171 The decline in both progression and relapse of EAE occurred as a result of reduced demyelina

172 At diagnosis or relapse of most hematologic neoplasms, malignant cells a

173 Despite novel therapies, relapse of multiple myeloma (MM) is virtually inevitable

174 stimulation parameters resulted in immediate relapse of status epilepticus, suggesting a pivotal role

175 ons, risk factors for adverse events and for relapse of systemic sting reaction, and a summary of gap

176 , no patients had a serious adverse event or relapse of vasculitis.

177 dvanced or metastatic breast cancer, who had relapsed on or after endocrine therapy and mTOR inhibito

178 gs; however, some patients remain at risk of relapse or death for many years after treatment of early

179 on of antidepressants may be associated with relapse or recurrence of depression, so the patient shou

180 bolic tumor volume (TMTV) could detect early relapse or refractory disease.

181 n 299 samples from 170 patients with locally relapsed or metastatic breast cancer.

182 as initial salvage therapy in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma

183 Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL)

184 limited regarding outcomes of patients with relapsed or refractory (rel/ref) DEL or DHL who undergo

185 consistent FLT3 inhibition in patients with relapsed or refractory acute myeloid leukaemia.

186 Ninety-five patients with relapsed or refractory acute myeloid leukemia (AML) were

187 lasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL on the basis

188 1 trial of 45 children and young adults with relapsed or refractory B-lineage acute lymphoblastic leu

189 Adult patients with relapsed or refractory chronic lymphocytic leukaemia (ac

190 led trial, adult patients (>/=18 years) with relapsed or refractory chronic lymphocytic leukaemia req

191 and favourable tolerability in patients with relapsed or refractory chronic lymphocytic leukaemia who

192 of care for the management of patients with relapsed or refractory chronic lymphocytic leukaemia.

193 Sixteen relapsed or refractory classic HL patients were included

194 9 cells can be effective in the treatment of relapsed or refractory diffuse large B-cell lymphoma and

195 s evaluated, 27 patients were diagnosed with relapsed or refractory disease and 12 died.

196 on (allo-HCT) is indicated for patients with relapsed or refractory Hodgkin lymphoma (HL).

197 12, 2015, to Jan 5, 2016, 124 patients with relapsed or refractory mantle cell lymphoma were enrolle

198 onse, and overall survival for patients with relapsed or refractory MCL receiving BR.

199 Novel therapies are needed for patients with relapsed or refractory multiple myeloma (MM).

200 up of patients with both newly diagnosed and relapsed or refractory multiple myeloma because it asses

201 a cohort of patients with newly diagnosed or relapsed or refractory multiple myeloma who were treated

202 f two proteasome inhibitors in patients with relapsed or refractory multiple myeloma.

203 to irinotecan-temozolomide in patients with relapsed or refractory neuroblastoma.

204 olerability of blinatumomab in patients with relapsed or refractory Ph(+) ALL.

205 ulticentre, international study, adults with relapsed or refractory, CD22-positive, Philadelphia chro

206 ell lymphoma or follicular lymphoma that had relapsed or was refractory to previous treatments.

207 ed with a two- to fourfold increased risk of relapse over 16-32 weeks.

208 ype (GT)1-infected treatment-naive and prior-relapse patients.

209 Relapsed patients also developed numerous mutations targ

210 toward advanced phase CML occurred, and all relapsing patients regained MMR and MR4.5 after restarti

211 ormation and the development of advanced and relapsed peritoneal metastasis and its impact on patient

212 The primary outcome was time to opioid relapse post-release in the community confirmed by urina

213 s prednisolone improves survival in men with relapsed prostate cancer.

214 reatments (38% +/- 3) but a markedly reduced relapse rate (44% +/- 3 vs 35% +/- 3) in favor of clofar

215 The relatively low relapse rate and high salvage rates at relapse reduce th

216 The annualized relapse rate and safety were assessed.

217 lthough early tumor response is encouraging, relapse rate is high and these compounds localize to the

218 nd function, lower viral infections, and low relapse rate posttransplant.

219 High relapse rates are attributed to pervasive nicotine-reinf

220 The PATH study compared relapse rates in patients given SCIg versus placebo.

221 b seem to have similar effects on annualised relapse rates in relapsing-remitting multiple sclerosis.

222 Significant differences in SVR12 and relapse rates were observed between CTP class A and CTP

223 y low relapse rate and high salvage rates at relapse reduce the potential benefit of maintenance ther

224 posomal irinotecan (nal-IRI) prevented tumor relapse, reduced metastasis, and increased both progress

225 antigen receptor-modified T cell therapy for relapsed/refractory acute lymphoblastic leukemia is lead

226 46% of patients following T cell therapy for relapsed/refractory acute lymphoblastic leukemia.

227 Methods In this study, 26 patients with relapsed/refractory ALK-positive ALCL and 14 patients wi

228 te the therapeutic potential of SGN-CD19B in relapsed/refractory B-NHL.

229 se escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autolog

230 Transplant-eligible patients with relapsed/refractory HL received 2 (cohort 1) or 3 (cohor

231 f PET-adapted therapy with BV and augICE for relapsed/refractory HL, bMTV and refractory disease were

232 tion of prognostic factors for patients with relapsed/refractory Hodgkin lymphoma (HL) is essential f

233 ralatrexate plus romidepsin in patients with relapsed/refractory lymphoma.

234 ngle-center, phase 2 study, 48 patients with relapsed/refractory MM (RRMM) received 28-day cycles of

235 In this phase 1 study, patients with relapsed/refractory MM received venetoclax monotherapy.

236 -agent antimyeloma activity in patients with relapsed/refractory MM, predominantly in patients with t

237 d dexamethasone 40 mg (QW), in patients with relapsed/refractory multiple myeloma (RRMM).

238 one (pom-dex) was evaluated in patients with relapsed/refractory multiple myeloma with >/=2 prior lin

239 Our data suggest that nivolumab is active in relapsed/refractory PCNSL and PTL and support further in

240 od and Drug Administration for patients with relapsed/refractory PTCL, exhibiting response rates of 2

241 The efficacy of pegylated ADI (ADI-PEG20) in relapsed/refractory/poor-risk acute myeloid leukemia (AM

242 s, follow-up of treatment, and management of relapse/remission cycles in multiple sclerosis patients

243 rom the cerebrospinal fluid of patients with relapsing remitting multiple sclerosis (RRMS) have highe

244 ctions of white matter lesion enlargement in relapsing remitting patients and is associated with grea

245 d progressive, as well as PLP138-151-induced relapsing-remitting experimental autoimmune encephalomye

246 d on the 2010 McDonald criteria (34 with the relapsing-remitting form, 2 with clinically isolated syn

247 , whereas the classifier that differentiates relapsing-remitting from progressive MS achieved a valid

248 Patients with relapsing-remitting MS (RRMS) or clinically isolated syn

249 atic carriers of HTLV-1 (AC), 47 HAM/TSP, 74 relapsing-remitting MS [RRMS], 17 secondary progressive

250 Ten relapsing-remitting MS patients were studied using the T

251 creased in peripheral blood of patients with relapsing-remitting MS with a high disease score.

252 ggestive of CNS demyelination and typical of relapsing-remitting multiple sclerosis, a complete neuro

253 lusion criteria were a diagnosis of definite relapsing-remitting multiple sclerosis, exposure to one

254 the first mAb approved for the treatment of relapsing-remitting multiple sclerosis.

255 milar effects on annualised relapse rates in relapsing-remitting multiple sclerosis.

256 with the CC genotype had significantly lower relapse risk in the GO arm than in the No-GO arm (26% v

257 We review the method of assessing CNS relapse risk, factors that increase the likelihood of re

258 to identify genetic variants that predict MS relapse risk, using a three-stage approach.

259 ixty-four matched samples-127 primary and 37 relapse samples-were analyzed by using RNA sequencing.

260 ls in the first-line and particularly in the relapse setting is highly recommended.

261 to chemotherapy and serve as reservoirs for relapse, showed significant suppression of TEs and inter

262 with shorter survival and a shorter time to relapse than was the absence of TP53 mutations, after ad

263 atment decision process, at diagnosis and at relapse, therefore requires myeloma physicians to carefu

264 We then tested them for relapse to aggression seeking after forced abstinence or

265 ological studies showed that context-induced relapse to alcohol-seeking was attenuated by bilateral m

266 K activity in the nucleus accumbens (NAc) in relapse to cocaine seeking.

267 SIGNIFICANCE STATEMENT: Relapse to cocaine use in a rat model is associated with

268 level using different animal models in which relapse to drug seeking is assessed after cessation of o

269 We then assessed relapse to drug seeking under extinction conditions afte

270 g reinstatement in a model of stress-induced relapse to drug taking.

271 High rates of relapse to drug use during abstinence is a defining feat

272 biopsies taken at both primary diagnosis and relapse, to investigate temporal gene expression differe

273 ent reactivity to an ordinarily subthreshold relapse trigger in a PrL-PFC CB1R activation-dependent m

274 Most studies investigating relapse use sputum samples although tissue bacteria may

275 Comparison of outcomes in patients with a relapsing vs nonrelapsing disease also were analyzed.

276 t female cocaine addicts experience enhanced relapse vulnerability compared with males, an effect tie

277 nduced molecular adaptations responsible for relapse vulnerability take place in astrocyte systems th

278 Cumulative incidence rate of first alcohol relapse was 25.2%, 33.7%, and 35.2% at 1, 3, and 5 years

279 In study 1, smoking relapse was associated with less gray-matter volume (F1,

280 A relapse was defined as loss of partial response.

281 nd Deauville criteria (91.4%) for predicting relapse was higher than CECT (40.3%) (P = 0.03 and P < 0

282 The hazard for relapse was lower with lisdexamfetamine than placebo.

283 The pooled proportion of relapse was significantly higher in arms with thrice wee

284 Alcohol relapse was similar in Group 1 versus Group 2: 23.5% ver

285 One patient who relapsed was retreated and has remained in partial respo

286 (NK) cells can decrease the risk of leukemia relapse, we initiated a phase 1 dose-escalation study of

287 Virological and clinical relapses were defined as viral DNA levels >2000 IU/mL an

288 ction against relapse, although it did delay relapse while patients were receiving antivirals.

289 e treatment with alternative medications, or relapse while receiving treatment with alternative medic

290 ce and understanding how the brain regulates relapse will be key to developing more effective behavio

291 vival and overall survival, and to correlate relapse with biomarkers.

292 thylation status was associated relapse (20% relapse with loss of heterozygosity, 25% with loss of im

293 osity, 25% with loss of imprinting, and 3.3% relapse with retention of the normal imprinting (P = 0.0

294 fier, and MRD <10(-4) had a very low risk of relapse, with a 5-year CIR of only 2%.

295 required for 4 patients as a result of FSGS relapse, with good results.

296 Three were on-drug relapses, with the CD19(-) escape variant first detected

297 onths, 5 of 107 patients experienced a local relapse within a median of 36.3 months.

298 al, cellular, and circuit mechanisms of drug relapse within the context of our session.

299 ve targeting of TH1/TH17 cells could inhibit relapses without causing John Cunningham virus-dependent

300 e in the circuitry that drives addiction and relapse, yet cocaine apparently has no effect on electri